When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Amgen(NASDAQ: AMGN) is about to get a piece of Celgene(NASDAQ: CELG). Sort of. To ease the way for the pending acquisition of Celgene by Bristol-Myers Squibb(NYSE: BMY) to close, Celgene is selling its psoriasis and psoriatic drug Otezla to Amgen for a cool $13.4 billion. It's a win-win-win deal.
But with all of the shuffling going on, which of these two big biotechs -- Amgen or Celgene -- is the better pick for investors hoping to win? The answer: It's complicated.